AgomAb Therapeutics NV (AGMB) vs Allogene Therapeutics (ALLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Allogene Therapeutics is the larger company by market cap ($483.7 million vs $454.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | ALLO |
|---|---|---|
| Share price | $9.22 | $1.40 |
| Market cap | $454.07M | $483.69M |
| 1-day change | +4.77% | -2.10% |
| YTD return | — | +2.19% |
| 1-year return | — | -4.76% |
| 5-year return | — | -91.50% |
| EPS (TTM) | $-2.16 | $-0.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $4.46 |
| 52-week low | $7.97 | $1.04 |
| Distance from 52-week high | -48.26% | -68.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +308.57% | +542.86% |
| Average volume | 139.21K | 5.65M |
| Shares outstanding | 49.25M | 345.49M |
| Employees | 62 | 150 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
AGMB vs ALLO FAQ
Which is bigger, AgomAb Therapeutics NV or Allogene Therapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $483.69M compared with $454.07M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Allogene Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.